Ranbaxy Laboratories is recalling some gabapentin tablets in the United

Ranbaxy Laboratories Ltd is recalling some gabapentin tablets in the United States. Ranbaxy is carrying out a voluntary recall of all lots of its 600mg and 800mg gabapentin tablets at the retail level as it found the presence of related substances permitted in the products to be outside the approved limit. According to a industry paper the recall involved 73 million tablets from the U.S. retail market, adding that Ranbaxy had a 2 percent share of the market for the specified dosages of the drug.